AVAX Technologies Completes First Step in Registering Its Lead Product, M-Vax, for Commercial Marketing and Distribution in France.

PHILADELPHIA -- AVAX Technologies, Inc. (OTCMarket:AVXT.OB) today announces that its wholly owned French subsidiary has been notified by AFSSAPS, the French regulatory authorities, that AVAX's facility in Lyon, France has received authorization for the production and distribution of AVAX's lead product M-Vax, the AC Vaccine therapeutic for the treatment of patients with melanoma. Under recently enacted regulations by AFSSAPS for individualized pharmaceutical products, the designation of a facility by AFSSAPS is the first step required for ultimate regulatory approval of an individualized product for distribution in France.

Under French regulations, a company is required to file with AFSSAPS two separate dossiers for cell or gene therapies. The first requires the company to demonstrate its ability to produce its products under current Good Manufacturing Practices (cGMP) conditions, while the second dossier requires the demonstration of the clinical effectiveness of the treatment.

AVAX has been notified by AFSSAPS that the AVAX dossier previously filed for the cGMP certification of the Lyon facility for the production of M-Vax has been approved by AFSSAPS, and the Lyon facility is now certified as cGMP compliant under the new French regulations for individualized cell and gene therapies.

The President of AVAX, Richard P. Rainey stated, "We are delighted to have achieved this designation, which is the result of a significant effort by our manufacturing team in Lyon, France. This designation satisfies the Company's requirements to demonstrate its ability to manufacture M-Vax in accordance with cGMP. Now that we have executed on the first requirements for obtaining regulatory authorization for M-Vax in France, our team is now in the process of finalizing the second dossier, which details the clinical effectiveness of M-Vax".

In addition to its commercialization program for M-Vax, AVAX is continuing to work to define the broad-based utility of its AC Vaccine Therapeutic in a range of solid tumors. The Company intends to source world-wide clinical and commercial programs for the AC Vaccine through its facility in Lyon, France.

About AVAX's AC Vaccine

AVAX's AC Vaccine platform is a therapeutic treatment for cancer. The AC Vaccines are prepared by attaching a small chemical to the patients tumor cells in a process known as haptenization. This hapten modification allows the tumor cells to stimulate a T cell-based immune response to a patients own tumor cells. An early indicator of T cell immune activity is delayed type hypersensitivity (DTH). A recently published article in the Journal of Clinical Oncology, February 2004 reported actual five-year survival data for a group of 214 patients with clinically evident Stage III melanoma treated with the AC Vaccine following surgery. The study demonstrated five-year survival of 45% and showed a highly statistically significant relationship between survival and DTH to patients' own tumor cells. Notably, based upon these results, DTH appears to be a viable "surrogate marker" for survival and an early indicator for clinical effectiveness of current and future product candidates. Previously clinical trials in ovarian and renal cell carcinoma, demonstrated strong DTH responses consistent with those reported for melanoma patients.

AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The Company is engaged in the research, clinical and commercial development of biological products and cancer therapeutics. In addition the Company offers contract-manufacturing services of biological products to other pharmaceutical and biotechnology companies.

Except for statements that are historical, the statements in this release are "forward-looking" statements that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by AVAX that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. Many important factors affect the Company's prospects, including (1) the Company's ability to obtain substantial additional capital to fund its development efforts, (2) the results of testing of its vaccine technologies, (3) possible future FDA or AFSSAPS questions regarding the Company's products and manufacturing processes, (4) the Company's ability to maintain its rights under license and research funding agreements and to meeting funding requirements under its license and research funding agreements, (5) the Company's ability to demonstrate the safety and efficacy of product candidates at each stage of development and to meet applicable regulatory standards and receive required regulatory approvals, as well as other risks detailed from time to time in AVAX's public disclosure filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2003 and its Registration Statement on Form SB-2 filed with the SEC. AVAX does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events.